Lumakras was approved by the FDA in May 2021 and was the first treatment for adult patients with non-small cell lung cancer with any KRAS mutation, according to a Sept. 12 news release from Amgen. In the study of 345 patients, people who took Lumakras went 5.6 months without their cancer progressing while people who took docetaxel went 4.5 months.
One-fourth of Lumakras patients lived for at least 1 year without their cancer getting worse. The same was true for 10 percent of chemotherapy patients.
The biopharmaceutical company said Lumakras showed a significantly higher overall response rate, an improved disease control rate and a faster and longer response compared to docetaxel.
Amgen could not prove that patients who took Lumakras lived longer, however, as this endpoint was not statistically significant.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
